DUTCH Weight Control in Atrial Fibrillation Study

Prior treatment

• Current or previous treatment with amiodaron
• Prior bariatric surgery
• Use of other anti-obesity medication, \<3 months prior to enrollment
• Contra-indication for, or prior use of a GLP1-receptor agonist
• Participation in another investigational drug or device study in the past 30 days (registry enrollment is allowed)

Other illness

• Secondary AF, i.e. due to thyrotoxicosis, infection (e.g. pneumonia) or post-(cardiothoracic) surgery
• History of diabetes mellitus type 1 or 2
• History of chronic pancreatitis or acute pancreatitis \<6 months
• Acute coronary syndrome \<6 months
• Severe (grade III) valvular disease
• Heart failure NYHA class III-IV
• Any condition or therapy, which would make the participant unsuitable for the study (e.g. vulnerable, non-compliance) or life-expectancy \<12 months, as judged by the treating physician.

Lab values

• HbA1c ≥ 48 mmol/mol, \<3 months prior to randomization
• eGFR \<30 mL/min/1.73m2

Other

• Permanent AF
• Female who is pregnant, breastfeeding, intends to become pregnant, or is of child-bearing potential and not using a highly effective contraceptive method.

• Symptomatic, first detected (at maximum 6 months prior to enrollment) persistent AF -
• Age ≥ 18
• Obesity, as defined as:
  • BMI ≥ 30 kg/m2, or
  • BMI ≥27 kg/m2 with the presence of at least one weight related comorbidity (treated or untreated, e.g. hypertension, dyslipidaemia, obstructive sleep apnea, cardiovascular disease)
• Scheduled ECV
• Written informed consent